A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), a non-invasive breast abnormality, according to data from a large, population-based study presented at the 2014 San Antonio Breast Cancer Symposium, held December 9 – 13.
The researchers say the test could provide important individualized information on the risk of recurrence after treatment by breast-conserving surgery, which can help better inform physicians and patients on their future risks and the need for additional treatment.
Katherine Woods, Senior Research Communications Manager at Breast Cancer Campaign, says:
“Research like this is crucial to the development of a reliable predictive test for women with DCIS, who at the moment face an agonising choice between risking the disease recurring after breast conserving surgery or facing potentially unnecessary further treatment, without knowing whether their DCIS will become life-threatening or not.
“While a test won’t be available overnight, we’re hopeful that ongoing research and knowledge sharing will make one possible in the future, which will signal a pivotal moment in the diagnosis and treatment of breast cancer.”